Immnophenotypic markers in AML: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
| Line 18: | Line 18: | ||
|colspan="1" style = "font-size:90%; color:black; width:15%;" |'''[[MPO]]''' | |colspan="1" style = "font-size:90%; color:black; width:15%;" |'''[[MPO]]''' | ||
|colspan="1" style = "font-size:90%;"|MPO is expressed in around 80% of cases of AML and in the absence of any other lineage defining features detection of MPO expression allows a diagnosis of AML to be made (see notes). | |colspan="1" style = "font-size:90%;"|MPO is expressed in around 80% of cases of AML and in the absence of any other lineage defining features detection of MPO expression allows a diagnosis of AML to be made (see notes). | ||
|- | |||
|colspan="1" style = "font-size:90%; color:black;" |'''Monocytic lineage''' can be assigned. | |||
|colspan="1" style = "font-size:90%;"|This requires detection of at least two of: [[CD14]], [[CD11c]], [[CD64]], [[NSE]], lysozyme* | |||
|- | |- | ||
|} | |} | ||
Revision as of 17:00, 20 December 2023
Table: Marker patterns that allow definite diagnosis of acute myeloid leukaemia
| Pattern 1: A myeloid lineage-defining marker pattern is present and No lineage-defining markers of T or B cells are present. | |
|---|---|
| MPO is the only "lineage-defining" marker of AML | |
| MPO | MPO is expressed in around 80% of cases of AML and in the absence of any other lineage defining features detection of MPO expression allows a diagnosis of AML to be made (see notes). |
| Monocytic lineage can be assigned. | This requires detection of at least two of: CD14, CD11c, CD64, NSE, lysozyme* |
| Pattern 2: At least two myeloid lineage-associated markers are present and there are no lineage defining markers of T or B cells and no more than one T-cell or B-cell lineage-associated marker is present | |
| A number of markers can be viewed as myeloid lineage associated | |
| CD117 | An early marker of myeloid lineage, seen in up to 80% of AML and vauable in recognising more primitive differentaiion forms (note that aberrant expression is seen in up to 20% of ALL cases) |
| CD33 | A good marker for AML, particularly for those cases with granulocytic maturation, CD33 is often less strongly expressed in AML with monocytic dfferentiation and strongly expressed in APL. |
| CD13 | A good lineage marker for AML that is acquired a little later in differentation than CD117 or CD33; expression of CD13 is often higher than CD33 in AML with monocytic differentiation. |